Publications by authors named "I Ros-Vilamajo"
Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry.
Arthritis Res Ther
February 2024
Background: Patients with Rheumatoid Arthritis (RA) have a higher prevalence of comorbidities compared to the general population. However, the implications of multimorbidity on therapeutic response and treatment retention remain unexplored.
Objectives: (a) To evaluate the impact of multimorbidity on the effectiveness of the first targeted synthetic or biologic disease-modifying antirheumatic drug (ts/bDMARD), in patients with RA after 2-year follow-up; (b) to investigate the influence of multimorbidity on treatment retention rate.
Introduction: Apremilast is approved for treatment of psoriasis and psoriatic arthritis (PsA). Real-world evidence on apremilast effectiveness in clinical practice is limited.
Methods: Observational study enrolling adult patients, across 21 Spanish centres, who had initiated apremilast in the prior 6 (±1) months and were biologic naive.
Objective: To investigate the influence of COVID-19 vaccination on disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients under targeted therapies.
Patients And Methods: 1765 vaccinated patients COVID-19, 1178 (66.7%) with RA and 587 (33.
Article Synopsis
- The study analyzed how common major central nervous system issues are in patients with systemic lupus erythematosus (SLE) and their impact on survival and mortality.
- Out of 3,591 SLE patients, 11.5% experienced significant CNS neuropsychiatric problems, leading to higher annual mortality rates, particularly from cerebrovascular disease and organic brain syndrome.
- The findings indicate that major CNS complications significantly increase mortality risk, with specific issues like CVD and organic brain syndrome having the worst survival outcomes.
Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis.
Musculoskeletal Care
March 2023
Aim: To assess the golimumab retention rate during up to 8 years of follow up, and any associated factors.
Methods: Retrospective analysis of the BIOBADASER (Spanish registry of biological drugs) database, assessing all adults who had ever started golimumab >6 months before the analysis for an approved indication (rheumatoid arthritis [RA], axial spondyloarthritis [SpA] or psoriatic arthritis [PsA]).
Results: Among 885 patients (RA 267, axial SpA 370, PsA 248) receiving 944 cycles of golimumab, the retention rate of golimumab was 71.